Company launches campaign to "counter" BMJ claims.
Moynihan
Ray
R
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D004345:Drug Industry; D005260:Female; D006801:Humans; D010506:Periodicals as Topic; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011641:Public Relations; D012109:Research Support as Topic; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy*
D010726:Phosphodiesterase Inhibitors; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human